Literature DB >> 17384343

Dual-energy X-ray absorptiometry study of body composition in patients with lipodystrophy.

Cynthia M Valerio1, Amélio Godoy-Matos, Rodrigo O Moreira, Lucia Carraro, Erika P Guedes, Regina S Moises, Patricia B Mory, Luciana Lopes de Souza, Luis Augusto Russo, Ana Cláudia Melazzi.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 17384343     DOI： 10.2337/dc07-0025

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  7 in total

Review 1.  What the genetics of lipodystrophy can teach us about insulin resistance and diabetes.

Authors:  Camille Vatier; Guillaume Bidault; Nolwenn Briand; Anne-Claire Guénantin; Laurence Teyssières; Olivier Lascols; Jacqueline Capeau; Corinne Vigouroux
Journal:  Curr Diab Rep       Date:  2013-12       Impact factor: 4.810

2.  Diagnostic Value of Anthropometric Measurements for Familial Partial Lipodystrophy, Dunnigan Variety.

Authors:  Chandna Vasandani; Xilong Li; Hilal Sekizkardes; Beverley Adams-Huet; Rebecca J Brown; Abhimanyu Garg
Journal:  J Clin Endocrinol Metab       Date:  2020-07-01       Impact factor: 5.958

3.  Body composition study by dual-energy x-ray absorptiometry in familial partial lipodystrophy: finding new tools for an objective evaluation.

Authors:  Cynthia M Valerio; Lenita Zajdenverg; José Egídio P de Oliveira; Patricia B Mory; Regina S Moyses; Amélio F Godoy-Matos
Journal:  Diabetol Metab Syndr       Date:  2012-08-31       Impact factor: 3.320

4.  Dipeptidyl peptidase-4 levels are increased and partially related to body fat distribution in patients with familial partial lipodystrophy type 2.

Authors:  Cynthia Melissa Valerio; Juliana Severo de Almeida; Rodrigo Oliveira Moreira; Luiza Barreto S Aguiar; Priscila O Siciliano; Denise P Carvalho; Amelio F Godoy-Matos
Journal:  Diabetol Metab Syndr       Date:  2017-04-24       Impact factor: 3.320

5.  Evaluation of the hypothalamic-pituitary-adrenal axis in a case series of familial partial lipodystrophy.

Authors:  Cecília Pacheco Elias; Daniela Espíndola Antunes; Michella Soares Coelho; Caroline Lourenço de Lima; Nelson Rassi; Ana Paula Meireles de Melo; Angélica Amorim Amato
Journal:  Diabetol Metab Syndr       Date:  2019-01-03       Impact factor: 3.320

6.  Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study.

Authors:  Maria C Foss-Freitas; Baris Akinci; Adam Neidert; Victoria J Bartlett; Eunju Hurh; Ewa Karwatowska-Prokopczuk; Elif A Oral
Journal:  Lipids Health Dis       Date:  2021-12-05       Impact factor: 3.876

7.  Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity.

Authors:  April Bingham; Gulnara Mamyrova; Kristina I Rother; Elif Oral; Elaine Cochran; Ahalya Premkumar; David Kleiner; Laura James-Newton; Ira N Targoff; Janardan P Pandey; Danielle Mercatante Carrick; Nancy Sebring; Terrance P O'Hanlon; Maria Ruiz-Hidalgo; Maria Turner; Leslie B Gordon; Jorge Laborda; Steven R Bauer; Perry J Blackshear; Lisa Imundo; Frederick W Miller; Lisa G Rider
Journal:  Medicine (Baltimore)       Date:  2008-03       Impact factor: 1.817
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.